The US AS biosimilar market — dramatically transformed by the wave of adalimumab biosimilar launches following the January 2023 Humira patent cliff — is creating competitive market dynamics that are progressively reducing anti-TNF biologic costs for US payers and creating formulary complexity for American AS patients and rheumatologists, with the US Sacroiliitis Treatment Market...